Senores Pharmaceuticals Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹36 Cr +0.9% YoYSee revenue, profit and what management said. You are viewing Q4 FY25.
SP

Senores Pharmaceuticals Ltd

Q4 FY25Pharmaceuticals & Biotechnology

Senores Pharmaceuticals Q4 FY25 earnings call: Revenue & Margins

Q4 FY25 earnings call: what management said on revenue, margins and capex.

Revenue
₹114Cr
+11.8% YoY
+10.7% QoQ
Net profit
₹18Cr
+28.6% YoY
+12.5% QoQ
Margin
17%
−5 pp YoY
−8 pp QoQ
Price₹1,513
Market cap₹6.8K Cr
P/E53.9

The short version

The company targets over 50% top-line growth for FY26, driven by both regulated and emerging markets. The company targets over 50% top-line growth in FY26 compared to FY25.

From Senores Pharmaceuticals Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • The company targets over 50% top-line growth for FY26, driven by both regulated and emerging markets.
  • Approximately 31 new ANDA product launches in the regulated market are expected in FY26.
  • Around 23 CDMO-CMO products are planned for commercialization in the current financial year.
  • Expansion in oral solids production capacity with two existing and two more lines being operational soon.
  • Emerging market product portfolio aims to grow to over 650 registered products by FY27.
  • Emerging market business margins expected to improve significantly, moving towards 15-16% EBITDA in 2 years.
  • PAT guidance for FY26 is a 100% increase compared to FY25, indicating strong profitability growth.
  • Growth driven by product mix changes, higher realizations, and strategic acquisitions.

2 more points from Senores Pharmaceuticals Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Senores Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Capex for FY26 is planned at INR 250 crores (Page 15).
  • Oral solids capacity expansion is ongoing with the 3rd line being installed and a 4th line planned to meet increased demand (Page 9).
  • New API facility (100-120 MTPA capacity) has commenced production; FDA trigger expected by Q2 2026 to support backward integration for US business (Pages 14-15).
  • The API facility primarily serves in-house needs with some external sales; it is positioned strategically rather than as a separate business vertical (Pages 14-15).
  • Focus is on changing product mix to improve realization and EBITDA margins (Page 10).

2 more points from Senores Pharmaceuticals Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Senores Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • Senores Pharmaceuticals has a strong order book and good visibility in its CDMO-CMO segment.
  • The company continues to see steady traction and scaling up in the CDMO-CMO segment.
  • The portfolio now includes about 22 commercial products in CDMO-CMO with around 69 products in the pipeline at various stages.
  • Many of these pipeline products are expected to be commercialized in the current fiscal year.
  • The company has a solid pipeline with plans to launch 31 ANDA (Abbreviated New Drug Applications) products in the regulated market and 23 CDMO-CMO products in the current financial year.

2 more points from Senores Pharmaceuticals Ltd's call on order book

Create a free account to keep reading this call

Senores Pharmaceuticals Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Senores Pharmaceuticals Ltd Q4 FY25 results — key figures

Senores Pharmaceuticals Ltd Q4 FY25 reported results vs Q4 FY24, ₹ crore
₹ CrQ4 FY25Q4 FY24YoYQ3 FY25QoQ
Revenue114102+11.8%103+10.7%
Operating profit (EBITDA)1922-13.6%26-26.9%
Operating margin17%22%-5 pp25%-8 pp
Profit before tax2118+16.7%20+5%
Net profit (PAT)1814+28.6%16+12.5%
EPS (₹)3.875.23-26%3.73+3.8%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹192 Cr, net profit ₹37 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Jubilant Pharmo (Q4 FY25)

    Q4 FY25 consolidated revenue grew 10% YoY to Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q4 FY25 earnings call — and how it ranks against sector…

  • Anuh Pharma (Q4 FY25)

    For Q4 FY 2025, operating revenue was ₹198.14 crore, a 2.24% year-on-year increase from ₹193.63 crore in Q4 FY 2024 (derived from annual total revenue…

  • Themis Medicare (Q4 FY25)

    71.70 Cr, down 27% YoY from Rs. Key concall takeaways from Themis Medicare Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.

  • Lincoln Pharmaceuticals (Q4 FY25)

    Revenue: $1.2 billion, representing a 5% increase year-on-year. Key concall takeaways from Lincoln Pharmaceuticals Ltd's Q4 FY25 earnings call — and how it…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Senores Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Senores Pharmaceuticals Ltd Q4 FY25 results?

The company targets over 50% top-line growth for FY26, driven by both regulated and emerging markets. The company targets over 50% top-line growth in FY26 compared to FY25.

What is Senores Pharmaceuticals Ltd share price analysis?

Senores Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 53.9 with a market cap of ₹6,805 Cr. Investors should review the full earnings analysis for detailed insights.

Is Senores Pharmaceuticals Ltd planning capital expenditure?

Capex for FY26 is planned at INR 250 crores (Page 15).

Keep Senores Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.